Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Pfizer Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while Pfizer Inc trades at $28.28 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 26.3× Iovance Biotherapeutics Inc. Common Stock's market cap, and Pfizer Inc pays a 6.18% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Pfizer Inc for 158 Days on average.
| IOVA | PFE | |
|---|---|---|
Market Cap | $6.04B | $158.56B |
Volume | 14,805,993 | 44,138,282 |
Sector | Health | Health |
52-Week High | $14.82 | $29.02 |
52-Week Low | $1.81 | $23.67 |
Typical Hold Time | 0 Days | 158 Days |
Enterprise Value | $5.97B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
